D.A. Davidson & CO. Has $324,000 Position in Adaptimmune Therapeutics PLC – (ADAP)
D.A. Davidson & CO. decreased its position in shares of Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) by 51.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 23,874 shares of the biotechnology company’s stock after selling 25,434 shares during the period. D.A. Davidson & CO.’s holdings in Adaptimmune Therapeutics were worth $324,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently added to or reduced their stakes in the stock. BNP Paribas Arbitrage SA acquired a new position in Adaptimmune Therapeutics during the 2nd quarter worth $122,000. BB&T Securities LLC acquired a new position in Adaptimmune Therapeutics during the 2nd quarter worth $128,000. BlackRock Inc. grew its holdings in Adaptimmune Therapeutics by 1.6% during the 3rd quarter. BlackRock Inc. now owns 775,405 shares of the biotechnology company’s stock worth $10,514,000 after acquiring an additional 12,113 shares in the last quarter. Raymond James Financial Services Advisors Inc. grew its holdings in Adaptimmune Therapeutics by 70.0% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 31,951 shares of the biotechnology company’s stock worth $379,000 after acquiring an additional 13,151 shares in the last quarter. Finally, Trexquant Investment LP acquired a new position in Adaptimmune Therapeutics during the 2nd quarter worth $178,000. 69.39% of the stock is currently owned by hedge funds and other institutional investors.
In other news, insider Gwendolyn Knowlt Binder-Scholl sold 25,000 shares of Adaptimmune Therapeutics stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $13.79, for a total value of $344,750.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 26.47% of the company’s stock.
Adaptimmune Therapeutics (NASDAQ:ADAP) last posted its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported $0.06 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.03) by $0.09. Adaptimmune Therapeutics had a negative net margin of 139.57% and a negative return on equity of 41.63%. The business had revenue of $40.79 million during the quarter, compared to analyst estimates of $29.41 million. As a group, equities research analysts expect that Adaptimmune Therapeutics PLC – will post -0.94 EPS for the current fiscal year.
Several research analysts have weighed in on ADAP shares. BidaskClub raised shares of Adaptimmune Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, August 24th. Cowen reissued a “buy” rating on shares of Adaptimmune Therapeutics in a report on Wednesday, August 15th. Guggenheim started coverage on shares of Adaptimmune Therapeutics in a report on Monday, September 17th. They set a “buy” rating for the company. Raymond James decreased their price objective on shares of Adaptimmune Therapeutics from $20.00 to $16.00 and set a “buy” rating for the company in a report on Monday, October 22nd. Finally, ValuEngine lowered shares of Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Sunday, October 28th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $15.44.
TRADEMARK VIOLATION NOTICE: This report was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.watchlistnews.com/d-a-davidson-co-has-324000-position-in-adaptimmune-therapeutics-plc-adap/2666861.html.
Adaptimmune Therapeutics Profile
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients.
Featured Article: Stock Split
Want to see what other hedge funds are holding ADAP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Adaptimmune Therapeutics PLC – (NASDAQ:ADAP).
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.